Gamma irradiation and targeted radionuclides enhance the expression of the noradrenaline transporter transgene controlled by the radio-inducible p21 WAF1/CIP1 promoter

Radiation Research

Volumn 179, Issue 3, 2013, Pages 282-292

  McCuskey, Anthony G ^a   Mairs, Robert J ^b   Sorensen, Annette ^a   Robson, Tracy ^c   McCarthy, Helen O ^c   Pimlott, Sally L ^d   Babich, John W ^e   Champion, Sue ^f   Boyd, Marie ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

^e Clinical Research   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CYCLIN DEPENDENT KINASE INHIBITOR 1; NORADRENALIN TRANSPORTER;

ARTICLE; COLORECTAL CARCINOMA; CYTOTOXICITY; EXPRESSION VECTOR; EXTERNAL BEAM RADIOTHERAPY; GAMMA IRRADIATION; GENE ACTIVATION; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOMA; HUMAN; HUMAN CELL; LINEAR ENERGY TRANSFER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENE;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GAMMA RAYS; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; TRANSGENES;

EID: 84874880595     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR3030.1     Document Type: Article

References (33)

1. Hallahan DE, Mauceri HJ, Seung LP, Dunphy JD, Wayne NN, Hanna A, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1(8):786-91.
2. Hallahan DE, Sukhatme VP, Sherman ML, Virudachalam S, Kuf D, Weichselbaum RR. Protein kinase C mediates x-ray inducibility of nuclear signal transducers EGR1 and JUN. Proc Natl Acad Sci U S A 1991; 88(6):2156-60.
3. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, et al. Radio-responsive recA promoter significantly increases TNF production in recombinant clostridia after 2 Gy irradiation. Gene Thera 2001; 8:1197-201.
4. Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo Jr. I, Barrett SF, et al. Induction by ionizing radiation of the gadd45 gene in cultured human cells: Lack of mediation by protein kinase C. Mol Cell Biol 1991; 11:1009-16.
5. Ueda T, Akiyama N, Sai H, Oya N, Noda M, Hiraoka M, et al. c-.IAP2 is induced by ionizing radiation through NF-kappaB binding sites. FEBS Lett 2001; 491(1-2):40-4.
6. Gartel AL, Serfas MS, Tyner AL. p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 1996; 213(2):138-49.
7. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci U S A 1999; 96(3):1002-7.
8. Biankin AV, Kench JG, Morey AL, Lee CS, Biankin SA, Head DR, et al. Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res 2001; 61(24):8830-7.
9. Codegoni AM, Nicoletti MI, Buraggi G, Valoti G, Giavazzi R, D'Incalci M, et al. Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer 1998; 34(9):1432-8.
10. O'Hanlon DM, Kiely M, MacConmara M, Al-Azzawi R, Connolly Y, Jeffers M, et al. An immunohistochemical study of p21 and p53expression in primary node-positive breast carcinoma. Eur J Surg Oncol 2002; 28(2):103-7.
11. Schwerer MJ, Sailer A, Kraft K, Baczako K, Maier H. Patterns of p21(waf1/cip1) expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas. J Clin Pathol 2001; 54(11):871-6.
12. Yook JI, Kim J. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol 1998; 34(3): 198-203.
13. Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment. J Gene Med 2004; 6(6):673-80.
14. Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7(13):1126-31.
15. Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: A novel suicide gene therapy. Gene Ther 2002; 9(4):263-9.
16. Vidal MJ, Loganzo F, de Oliveira AR, Hayward NK, Albino AP. Mutations and defective expression of the WAF1 p21 tumoursuppressor gene in malignant melanomas. Melanoma Res 1995; 5(4):243-50.
17. Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM. p21(WAF1/CIP1) expression in stage I cutaneous malignant melanoma: Its relationship with p53, cell proliferation and survival. Br J Cancer 1999; 79(5-6):895-902.
18. Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE. Noradrenaline transporter gene transfer for radiation cell kill by [131I]meta- iodobenzylguanidine. Gene Therapy 1999; 6:1147-52.
19. Fullerton NE, Mairs RJ, Kirk D, Keith WN, Carruthers R, McCluskey AG, et al. Application of targeted radiotherapy/gene therapy to bladder cancer cell lines. Europn Urolo 2005; 47(2): 250-6.
20. Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, et al. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects. J Gene Medicine 2004; 6:937-47.
21. Boyd M, Ross S, Owens J, Hunter D, Babich J, Zalutsky MR, et al. Preclinical evaluation of no-carrier-Added [131I]meta-iodobenzylguanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 2004; 1:50-7.
22. Vaidyanathan G, Affleck DJ, Alston KL, Zhao XG, Hens M, Hunter DH, et al. A kit method for the high level synthesis of [211At]MABG. Bioorg Med Chem 2007; 15(10):3430-6.
23. Mairs RJ, Fullerton NE, Zalutsky MR, Boyd M. Targeted radiotherapy; microgray doses and the bystander effect. Dose-.Response 2007; 5:204-13.
24. McCarthy H, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, et al. p21(WAF-1)-mediated transcriptional targeting of iNOS gene therapy sensitizes tumours to fractionated radiotherapy. Gene Ther 2007; 14:246-55.
25. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981 41:1751-6.
26. Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of [131I]meta-iodobenzylguanidine by neuroblastoma tumours. Clin Cancer Res 2003; 9(9): 3338-44.
27. Hunter DH, Zhu X. Polymer-supported radiopharmaceuticals: [131I]MIBG and [123I]MIBG. J Lab Comp Radiopharm 1999; 42:653-61.
28. Vaidyanathan G, Zalutsky MR. No-carrier-Added synthesis of meta-[131I]iodobenzylguanidine. Appl Radiat Isot 1993; 44:621-8.
29. Wieland DM, Brown LE, Tobes MC, Rogers WL, Marsh D, Mangner TJ, et al. Imaging the primate adrenal medulla with [125I] and [131I] metaiodobenzylguanidine: Concise communication. J Nucl Med 1981; 22:358-64.
30. Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of metaiodobenzylguanidine by bovine chromaffin granule membranes. Molec Pharmacol 1986; 29:275-.80.
31. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with a-, b-, and auger electron-emitting radionuclides. J Nucl Med 2006; 47:1007-.15.
32. Mairs RJ, Ross SC, McCluskey AG, Boyd M. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo. J Nucl Med 2007; 48(9): 1519-26.
33. Sorensen S, Mairs RJ, Braidwood L, Joyce C, Conner J, Pimlott SL, et al. In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy. J Nucl Med 2012; 53(4):647-54.